Scaling Down of Biopharmaceutical Unit Operations — Part 2: Chromatography and Filtration - Constraints associated with equipment can make scale-down a challenging exercise. - BioPharm

ADVERTISEMENT

Scaling Down of Biopharmaceutical Unit Operations — Part 2: Chromatography and Filtration
Constraints associated with equipment can make scale-down a challenging exercise.


BioPharm International


However, there are considerations unique to each unit operation that apply during scale-down. Constraints associated with equipment or methodology may prevent a "true" scale-down of a unit operation. Dead volumes and hold times are typically greater at manufacturing scale. Path lengths of detectors typically vary between instruments at the lab and the manufacturing plant. Wetted materials (gaskets, valves, and pumps) are not likely to be the same at two scales. Differences in cassette design between two scales may impact the outcome of lifetime studies of UF and DF membranes.

Scale-down studies certainly increase the chances for a successful validation campaign, but they only provide "guidance." The actual "confirmation" must be made at large scale. The only exception to this is the viral-clearance validation studies that are performed at small scale.

Anurag Rathore, is a principal scientist at Amgen Inc., 30W-2-A, One Amgen Center Drive, Thousand Oaks, CA 91320, 805.447.4491, fax 805.499.5008,
Raj Krishnan and Stephanie Tozer work for Amgen Inc, Thousand Oaks, CA. Dave Smiley, Steve Rausch and Jim Seely work for Amgen Inc., Longmont, CO. Anurag Rathore is a member of the Editorial Advisory Board.

REFERENCES 1. ICH, Quality of biotechnological products: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. International Conference on Harmonization Step 4 Endorsement 1997 March. Available at: http://www.fda.gov/cder/guideance/Q5A-fnl.pdf

2. Yamamoto S, Nomura M, Sano Y, Resolution of proteins in linear gradient elution ion exchange and hydrophobic interaction chromatography. J. Chromatogr. 1987:409:101-110.O'Leary RM, Feuerheim D, Peers D, Xu Y, Blank GS. Determining the useful lifetime of chromatography resins, Biopharm Int. 2001 Sept.; 14 (9):10-18.4.Rathore AS, Velayudhan A. Scale-up guidelines for preparative chromatography, Biopharm Int'l. 2003 Jan.; 16 (1):34-42.

3. O'Leary RM, Feuerheim D, Peers D, Xu Y, Blank GS. Determining the useful lifetime of chromatography resins, Biopharm Int'l. 2001 Sept.; 14 (9):10-18.4.

4. Rathore AS, Velayudhan A. Scale-up guidelines for preparative chromatography, Biopharm Int'l. 2003 Jan.; 16 (1):34-42.

5. Rathore AS, Wang A, Menon M, Riske F, Campbell J, Goodrich E, Martin J. Optimization, scale-up and validation issues in filtration of biopharmaceuticals - Part I. Biopharm Int'l. 2004 August; 17 (8):50-58.

6. Lutz H, Siwak M, Carter J. Viral clearance performance and regulatory requirements, Poster, Biophex/Interphex, 2002 October 23-24; Santa Clara, CA.

7. Rathore AS, Sharma A, Zhang RJ, Chilin D. Scale-down modeling and characterization of a protein refolding step, Oral presentation, 227th American Chemical Society National Meeting, 2004 March 28-April 1; Anaheim, CA.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here